In addition to MF, HEARTS is also delivered to patients with other diagnoses, such as therapy-refractory cutaneous CD4+ T-cell lymphoma, refractory acute myelogenous leukemia with extensive cutaneous involvement, and primary cutaneous T-cell lymphoma [28,92,93,95]. Here, CD4 is linked to T-cell non-Hodgkin lymphoma.